AGO61-dependent GlcNAc modification primes the formation of functional glycans on α-dystroglycan

Scientific Reports

Volumn 3, Issue , 2013, Pages

  Yagi, Hirokazu ^a   Nakagawa, Naoki ^b   Saito, Takuya ^a   Kiyonari, Hiroshi ^c   Abe, Takaya ^c   Toda, Tatsushi ^d   Wu, Sz Wei ^e   Khoo, Kay Hooi ^e   Oka, Shogo ^b   Kato, Koichi ^a,f  

^a NAGOYA CITY UNIVERSITY   (Japan)

^b KYOTO UNIVERSITY   (Japan)

^c RIKEN Center for Biosystems Dynamics Research   (Japan)

^d KOBE UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^e INSTITUTE OF BIOLOGICAL CHEMISTRY   (Taiwan)

^f OKAZAKI INSTITUTE FOR INTEGRATIVE BIOSCIENCE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

AGO61 PROTEIN, MOUSE; DYSTROGLYCAN; GLUCOSAMINE; GLYCOSYLTRANSFERASE; LAMININ; N ACETYLGLUCOSAMINYLTRANSFERASE; PEPTIDE; POLYSACCHARIDE; RECOMBINANT PROTEIN;

ANIMAL; BIOSYNTHESIS; CELL LINE; CHEMISTRY; CHLOROCEBUS AETHIOPS; COS 1 CELL LINE; DEFICIENCY; GENETICS; KNOCKOUT MOUSE; METABOLISM; MOUSE; MUTATION; PHOSPHORYLATION; TANDEM MASS SPECTROMETRY;

ANIMALS; CELL LINE; CERCOPITHECUS AETHIOPS; COS CELLS; DYSTROGLYCANS; GLUCOSAMINE; GLYCOSYLTRANSFERASES; LAMININ; MICE; MICE, KNOCKOUT; MUTATION; N-ACETYLGLUCOSAMINYLTRANSFERASES; PEPTIDES; PHOSPHORYLATION; POLYSACCHARIDES; RECOMBINANT PROTEINS; TANDEM MASS SPECTROMETRY;

EID: 84888236335     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep03288     Document Type: Article

References (37)

1. Michele, D. E. & Campbell, K. P. Dystrophin-glycoprotein complex: Posttranslational processing and dystroglycan function. J. Biol. Chem. 278, 15457-60 (2003).
2. Muntoni, F., Torelli, S. & Brockington, M. Muscular dystrophies due to glycosylation defects. Neurotherapeutics 5, 627-32 (2008).
3. Holt, K. H., Crosbie, R. H., Venzke, D. P. & Campbell, K. P. Biosynthesis of dystroglycan: Processing of a precursor propeptide. FEBS Lett. 468, 79-83 (2000).
4. Ibraghimov-Beskrovnaya, O. et al. Primary structure of dystrophin-associated glycoproteins linking dystrophin to the extracellular matrix. Nature 355, 696-702 (1992).
5. Barresi, R. & Campbell, K. P. Dystroglycan: From biosynthesis to pathogenesis of human disease. J. Cell Sci. 119, 199-207 (2006).
6. Beltran-Valero de Bernabe, D. et al.Mutations in the O- mannosyltransferase gene POMT1 give rise to the severe neuronal migration disorder Walker-Warburg syndrome. Am. J. Hum. Genet. 71, 1033-43 (2002).
7. Manya, H. et al. Demonstration of mammalian protein O-mannosyltransferase activity: Coexpression of POMT1 and POMT2 required for enzymatic activity. Proc. Natl. Acad. Sci. U.S.A. 101, 500-5 (2004).
8. van Reeuwijk, J. et al. POMT2 mutations cause a-dystroglycan hypoglycosylation and Walker-Warburg syndrome. J. Med. Genet. 42, 907-12 (2005).
9. Yoshida, A. et al.Muscular dystrophy and neuronal migration disorder caused by mutations in a glycosyltransferase, POMGnT1. Dev. Cell 1, 717-24 (2001).
10. Carss, K. J. et al. Mutations in GDP-mannose pyrophosphorylase B cause congenital and limb-girdle muscular dystrophies associated with hypoglycosylation of a-dystroglycan. Am. J. Hum. Genet. 93, 29-41 (2013).
11. Longman, C. et al. Mutations in the human LARGE gene cause MDC1D, a novel form of congenital muscular dystrophy with severe mental retardation and abnormal glycosylation of a-dystroglycan. Hum. Mol. Genet. 12, 2853-61 (2003).
12. Inamori, K. et al. Dystroglycan function requires xylosyl-and glucuronyltransferase activities of LARGE. Science 335, 93-6 (2012).
13. Yoshida-Moriguchi, T. et al. O-mannosyl phosphorylation of a-dystroglycan is required for laminin binding. Science 327, 88-92 (2010).
14. Kobayashi, K. et al. An ancient retrotransposal insertion causes Fukuyama-type congenital muscular dystrophy. Nature 394, 388-92 (1998).
15. Brockington, M. et al.Mutations in the fukutin-related protein gene (FKRP) cause a form of congenital muscular dystrophy with secondary laminin a2 deficiency and abnormal glycosylation of a-dystroglycan. Am. J. Hum. Genet. 69, 1198-209 (2001).
16. Buysse, K. et al. Missense mutations in b-1,3-N- acetylglucosaminyltransferase 1 (B3GNT1) cause Walker-Warburg syndrome. Hum. Mol. Genet. 22, 1746-54 (2013).
17. Roscioli, T. et al. Mutations in ISPD cause Walker-Warburg syndrome and defective glycosylation of a-dystroglycan. Nat. Genet. 44, 581-5 (2012).
18. Willer, T. et al. ISPD loss-of-function mutations disrupt dystroglycan Omannosylation and cause Walker-Warburg syndrome. Nat. Genet. 44, 575-80 (2012).
19. Vuillaumier-Barrot, S. et al. Identification of mutations in TMEM5 and ISPD as a cause of severe cobblestone lissencephaly. Am. J. Hum. Genet. 91, 1135-43 (2012).
20. Manzini, M. C. et al. Exome sequencing and functional validation in zebrafish identify GTDC2 mutations as a cause of Walker-Warburg syndrome. Am. J. Hum. Genet. 91, 541-7 (2012).
21. Yoshida-Moriguchi, T. et al. SGK196 is a glycosylation-specificO-mannose kinase required for dystroglycan function. Science 341, 896-899 (2013).
22. Stevens, E. et al. Mutations in B3GALNT2 cause congenital muscular dystrophy and hypoglycosylation of a-dystroglycan. Am. J. Hum. Genet. 92, 354-65 (2013).
23. Jae, L. T. et al.Deciphering the glycosylome of dystroglycanopathies using haploid screens for lassa virus entry. Science 340, 479-83 (2013).
24. Chiyonobu, T. et al. Effects of fukutin deficiency in the developing mouse brain. Neuromuscul. Disord. 15, 416-26 (2005).
25. Satz, J. S. et al. Distinct functions of glial and neuronal dystroglycan in the developing and adult mouse brain. J. Neurosci. 30, 14560-72 (2010).
26. Wright, K. M. et al. Dystroglycan organizes axon guidance cue localization and axonal pathfinding. Neuron 76, 931-44 (2012).
27. Kanagawa, M. et al. Residual laminin-binding activity and enhanced dystroglycan glycosylation by LARGE in novel model mice to dystroglycanopathy. Hum. Mol. Genet. 18, 621-31 (2009).
28. Yu, M. et al. Adeno-associated viral-mediated LARGE gene therapy rescues the muscular dystrophic phenotype in mouse models of dystroglycanopathy. Hum Gene Ther. 24, 317-30 (2013).
29. Isono, T. O-GlcNAc-specific antibody CTD110.6 cross-reacts with N-GlcNAc2-modified proteins induced under glucose deprivation. PLoS One 6, e18959 (2011).
30. Hara, Y. et al. Like-acetylglucosaminyltransferase (LARGE)-dependent modification of dystroglycan at Thr-317/319 is required for laminin binding and arenavirus infection. Proc. Natl. Acad. Sci. U.S.A. 108, 17426-31 (2011).
31. Nakagawa, N., Takematsu, H. & Oka, S. HNK-1 sulfotransferase- dependent sulfation regulating laminin-binding glycans occurs in the post-phosphoryl moiety on a-dystroglycan. Glycobiology (2013).
32. Gomez Toledo, A. et al. O-Mannose and O-N-acetyl galactosamine glycosylation of mammalian a-dystroglycan is conserved in a region-specific manner. Glycobiology 22, 1413-23 (2012).
33. Stalnaker, S. H. et al. Site mapping and characterization of O-glycan structures on a-dystroglycan isolated from rabbit skeletal muscle. J. Biol. Chem. 285, 24882-91 (2010).
34. Nilsson, J., Larson, G. & Grahn, A. Characterization of site-specific O-glycan structures within the mucin-like domain of a-dystroglycan from human skeletal muscle. Glycobiology 20, 1160-9 (2010).
35. Kuga, A. et al. Absence of post-phosphoryl modification in dystroglycanopathy mouse models and wild-type tissues expressing non-laminin binding form of adystroglycan. J. Biol. Chem. 287, 9560-7 (2012).
36. Nakagawa, N., Manya, H., Toda, T., Endo, T. & Oka, S. Human natural killer-1 sulfotransferase (HNK-1ST)-induced sulfate transfer regulates laminin-binding glycans on a-dystroglycan. J. Biol. Chem. 287, 30823-32 (2012).
37. Yagi, H. et al. HNK-1 epitope-carrying tenascin-C spliced variant regulates the proliferation of mouse embryonic neural stem cells. J. Biol. Chem. 285, 37293-301 (2010).